Literature DB >> 22981881

Increased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging.

Assimina Argyriou1, Georgia Dermentzaki, Themistoklis Papasilekas, Marina Moraitou, Eleftherios Stamboulis, Kostas Vekrellis, Helen Michelakakis, Leonidas Stefanis.   

Abstract

Gaucher disease (GD) patients and carriers of glucocerebrosidase mutations are at an increased risk for Parkinson's disease (PD). The presynaptic protein alpha-synuclein (AS) is linked to PD. In the current work we examined biochemical properties of AS in GD patients. We generated membrane-enriched lysates from erythrocytes of 27 patients with GD and 32 age- and sex-matched controls and performed Western immunoblotting with antibodies against AS. Levels of monomeric AS did not differ between GD patients and controls and did not change as a function of age. However, the ratio of dimeric to monomeric AS was significantly increased in GD patients, and showed a significant positive correlation with age. Therefore, two major risk factors for PD, aging and GD status, are associated with an increased AS dimer to monomer ratio in erythrocytes. This ratio needs to be validated in further studies as a potential biomarker for PD risk.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22981881     DOI: 10.1016/j.neulet.2012.08.069

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

Review 1.  GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.

Authors:  Parker H Johnson; Neal J Weinreb; James C Cloyd; Paul J Tuite; Reena V Kartha
Journal:  Mol Genet Metab       Date:  2019-10-23       Impact factor: 4.797

2.  Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.

Authors:  Ianai Fishbein; Yien-Ming Kuo; Benoit I Giasson; Robert L Nussbaum
Journal:  Brain       Date:  2014-10-27       Impact factor: 13.501

Review 3.  Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease.

Authors:  Ziv Gan-Or; Patrick A Dion; Guy A Rouleau
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

4.  Glucocerebrosidase and parkinsonism: lessons to learn.

Authors:  Ivanka Marković; Nikola Kresojević; Vladimir S Kostić
Journal:  J Neurol       Date:  2016-03-19       Impact factor: 4.849

5.  Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.

Authors:  Chandana Buddhala; Meghan C Campbell; Joel S Perlmutter; Paul T Kotzbauer
Journal:  Neurobiol Aging       Date:  2014-08-04       Impact factor: 4.673

6.  Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity.

Authors:  Mustafa T Ardah; Katerina E Paleologou; Guohua Lv; Salema B Abul Khair; Abdulla S Kazim; Saeed T Minhas; Taleb H Al-Tel; Abdulmonem A Al-Hayani; Mohammed E Haque; David Eliezer; Omar M A El-Agnaf
Journal:  Front Aging Neurosci       Date:  2014-08-05       Impact factor: 5.750

Review 7.  Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease.

Authors:  Luis M A Oliveira; Thomas Gasser; Robert Edwards; Markus Zweckstetter; Ronald Melki; Leonidas Stefanis; Hilal A Lashuel; David Sulzer; Kostas Vekrellis; Glenda M Halliday; Julianna J Tomlinson; Michael Schlossmacher; Poul Henning Jensen; Julia Schulze-Hentrich; Olaf Riess; Warren D Hirst; Omar El-Agnaf; Brit Mollenhauer; Peter Lansbury; Tiago F Outeiro
Journal:  NPJ Parkinsons Dis       Date:  2021-07-26

8.  Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells.

Authors:  Georgia Dermentzaki; Evangelia Dimitriou; Maria Xilouri; Helen Michelakakis; Leonidas Stefanis
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.